Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1

Interventions

Doxorubicin 62Ifosfamide 39Gemcitabine 29Radiotherapy 27Filgrastim 27Cyclophosphamide 26Docetaxel 19Vincristine 18pembrolizumab 17Etoposide 17pazopanib 16Cisplatin 16Nivolumab 15Trabectedin 14apatinib 13Magnetic Resonance Spectroscopy 13Carboplatin 12Irinotecan 11Bevacizumab 11anlotinib 10Temozolomide 10Surgical Procedures, Operative 10Sirolimus 10camrelizumab 9Sorafenib 9Paclitaxel 9Ipilimumab 9Injections 9Dactinomycin 9Topotecan 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma × trebananib × Clear all
NCT01623869 2015-10-19

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 6 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡